Glasgow prognostic score is a better predictor of the long-term survival in patients with gastric cancer, compared to the modified Glasgow prognostic score or high-sensitivity modified Glasgow prognostic score.

Background: Inflammation influences cancer progression by increasing catabolism and impairing nutrient absorption. We compared the prognostic ability of three inflammation-based prognostic scoring systems-the Glasgow prognostic score (GPS), modified GPS (mGPS), and high-sensitivity mGPS (HS-mGPS)-in gastric cancer patients.

Materials And Methods: We retrospectively examined 434 curatively resected gastric cancer patients to evaluate the prognostic ability of scoring systems for overall survival (OS) and cancer-specific survival (CSS).

Results: OS analysis identified the following independent prognostic factors: GPS model: pathological stage (pStage, < 0.001), carcinoembryonic antigen (CEA, = 0.004), and GPS 1 (hazard ratio [HR], 1.929; 95% confidence interval [CI], 1.152-3.228; = 0.013); mGPS model: body mass index (BMI, = 0.027), pStage ( < 0.001), and CEA ( < 0.001); HS-mGPS model: BMI ( = 0.029), pStage ( < 0.001), and CEA ( = 0.003). mGPS and HS-mGPS were not independent prognostic factors for OS. CSS analysis of the GPS model identified pStage ( < 0.001), CEA ( = 0.015), and GPS 1 (HR; 2.095, 95% CI; 1.025-4.283; = 0.043) and 2 (HR, 2.812; 95% CI, 1.111-7.116; = 0.029) as independent prognostic factors; however, mGPS and HS-mGPS were not independent prognostic factors for CSS. Log-rank tests demonstrated significant differences in OS among patients with GPS 0 vs. 1 ( < 0.001) and 0 vs. 2 ( < 0.001) and in CSS among the three GPS (0 vs. 1; = 0.005, 0 vs. 2; < 0.001, 1 vs. 2; = 0.009).

Conclusions: GPS most reliably predicts long-term survival of gastric cancer patients.